Loading organizations...
Loading organizations...
Huaguan Biotechnology: Drug R&D services using synthetic biology and green chemistry for pharmaceutical and biotech sectors.
Huaguan Biotechnology, a Beijing-based firm, provides integrated drug research and development services, specializing in synthetic biology and green chemistry. Leveraging enzymatic chemical synthesis with a resource library of tens of thousands of catalytic enzymes and continuous-flow technology, the company operates a complete technology closed-loop from R&D to commercial production. It operates a 100-ton-scale GMP production base of over 61,000 square meters in Inner Mongolia, with R&D centers in Beijing and Nanjing, and holds 11 patents. Serving pharmaceutical and biotech sectors, with clients including Sihuan Pharmaceutical and Sichuan, the firm secured hundreds of millions of yuan in Series funding from investors like Changzhou Qihang Synthetic Biology Venture Capital Fund, including partner Wang Chunping. The company was founded in 2018 by Dr. Chen Jian.
Huaguan Biotechnology has raised $28.4M across 2 funding rounds.
Huaguan Biotechnology specializes in providing integrated drug research and development services, offering comprehensive solutions across various stages of pharmaceutical development.
Huaguan Biotechnology provides services to customers that have included Sihuan Pharmaceutical, among others.
Huaguan Biotechnology specializes in providing integrated drug research and development services, offering comprehensive solutions across various stages of pharmaceutical development.
Huaguan Biotechnology provides services to customers that have included Sihuan Pharmaceutical, among others.
Huaguan Biotechnology, headquartered in Beijing, China, is a specialized provider of integrated drug research and development services. Established in 2017, the company operates within the dynamic biotechnology sector, offering comprehensive solutions designed to support the complex process of pharmaceutical innovation. Its mission centers on delivering high-quality services to its clients, which have included organizations such as Sihuan Pharmaceutical.
The firm's expertise lies in its ability to offer end-to-end R&D support. This integrated approach ensures that clients can access a broad spectrum of services required for advancing drug candidates from discovery through various developmental stages. Huaguan Biotechnology's focus on quality aims to meet the stringent demands of the pharmaceutical industry.
As a key player in the Chinese biotechnology landscape, Huaguan Biotechnology contributes to the nation's scientific and medical progress. Its strategic location in Beijing places it within a vibrant hub for technological and scientific development, facilitating collaborations and access to talent.
Huaguan Biotechnology has demonstrated its financial viability and growth potential through successful fundraising initiatives. The company recently completed a Series C financing round, which secured hundreds of millions of RMB. This significant investment underscores investor confidence in its business model and its capacity for future expansion within the biotechnology market.
The capital raised from its Series C round is intended to bolster its operational capabilities, enhance its service offerings, and potentially expand its market reach. This funding enables Huaguan Biotechnology to continue its trajectory as a specialized service provider, supporting the development of new therapeutic solutions.
Huaguan Biotechnology has raised $28.4M across 2 funding rounds. Most recently, it raised $14.4M Series C in February 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 4, 2026 | $14.4M Series C | Changjiang Capital, Changzhou Qihang Synthetic Biology Venture Capital Fund, SDIC Venture Capital, Shunxi Fund, Zhuhai Hengqin Softbank Xinchuang Equity Investment Management Enterprise | |
| Sep 27, 2022 | $14.0M Series B |